

POLICY: Amyloidosis – Wainua Utilization Management Medical Policy

- Wainua™ (eplontersen subcutaneous injection – AstraZeneca)

EFFECTIVE DATE: 5/15/2024

LAST REVISION DATE: 1/03/2024

COVERAGE CRITERIA FOR: All Aspirus Medicare Plans

OVERVIEW

Wainua, a transthyretin (TTR)-directed antisense oligonucleotide, is indicated for the treatment of the **polyneuropathy of hereditary transthyretin-mediated amyloidosis (hATTR)** in adults.¹ Wainua has not been studied in patients with prior liver transplantation. hATTR is a progressive disease caused by mutations in the TTR gene leading to multisystem organ dysfunction.² Common neurologic manifestations include sensorimotor polyneuropathy, autonomic neuropathy, small-fiber polyneuropathy, and carpal tunnel syndrome.

Guidelines

There are no guidelines that include recommendations for Wainua. A scientific statement from the American Heart Association (AHA) on the treatment of the cardiomyopathy of hATTR amyloidosis (July 2020) includes recommendations related to polyneuropathy.³ Canadian guidelines for the treatment of patients with polyneuropathy (February 2021) and recommendations from the European Society of Cardiology (ESC) [2021] include treatment recommendations for hATTR polyneuropathy as well.^{2,4} In general, Onpattro® (patisiran intravenous infusion) and Tegsedi® (inotersen subcutaneous injection) are recommended for patients with hATTR polyneuropathy.

For patients with hATTR amyloidosis with polyneuropathy, the AHA recommends treatment with Onpattro or Tegsedi.³ For patients with hATTR with polyneuropathy and cardiomyopathy, Onpattro, Tegsedi, or Vyndamax® (tafamidis meglumine capsules)/Vyndaqel™ (tafamidis capsules) are recommended. Use of combination therapy is discussed; however, it is noted that there is little data to support combination therapy.

The Canadian guidelines recommend Onpattro and Tegsedi as first-line treatment to stop the progression of neuropathy and improve polyneuropathy in early and late stage hATTR amyloidosis with polyneuropathy.²

The ESC Guidelines for the diagnosis and treatment of acute and chronic heart failure note that TTR stabilization and reduction are the recommended basis of treatment for cardiomyopathy of hATTR.⁴ Onpattro and Tegsedi may be considered for patients with hATTR polyneuropathy and cardiomyopathy.

POLICY STATEMENT

Prior Authorization is recommended for medical benefit coverage of Wainua. Approval is recommended for those who meet the **Criteria** and **Dosing** for the listed indication. Extended approvals are allowed if the patient continues to meet the Criteria and Dosing. Requests for doses outside of the established dosing documented in this policy will be considered on a case-by-case basis by a clinician (i.e., Medical Director or Pharmacist). All approvals are provided for the duration noted below. Because of the specialized skills required for evaluation and diagnosis of patients treated with Wainua as well as the monitoring required for

adverse events and long-term efficacy, approval requires Wainua to be prescribed by or in consultation with a physician who specializes in the condition being treated.

Automation: None.

RECOMMENDED AUTHORIZATION CRITERIA

Coverage of Wainua is recommended in those who meet the following criteria:

FDA-Approved Indication

- 1. Polyneuropathy of Hereditary Transthyretin-Mediated Amyloidosis (hATTR).** Approve for 1 year if the patient meets ALL of the following (A, B, C, D, and E):
 - A) Patient is ≥ 18 years of age; AND
 - B) Patient has a transthyretin mutation as confirmed by genetic testing; AND
 - C) Patient has symptomatic polyneuropathy; AND
Note: Examples of symptomatic polyneuropathy include reduced motor strength/coordination, and impaired sensation (e.g., pain, temperature, vibration, touch). Examples of assessments for symptomatic disease include history and clinical exam, electromyography, or nerve conduction velocity testing.
 - D) Patient does not have a history of liver transplantation; AND
 - E) The medication is prescribed by or in consultation with a neurologist, geneticist, or a physician who specializes in the treatment of amyloidosis.

Dosing. Approve 45 mg subcutaneously once monthly.

CONDITIONS NOT RECOMMENDED FOR APPROVAL

Coverage of Wainua is not recommended in the following situations:

- 1. Concomitant Use With Amvuttra (vutrisiran subcutaneous injection), Onpattro (patisiran intravenous infusion), Tegsedi (inotersen subcutaneous injection), or a Tafamidis Product.**
Note: Examples of tafamidis products are Vyndaqel and Vyndamax.
There are insufficient data supporting the safety and efficacy of concurrent use of these agents for hereditary transthyretin-mediated amyloidosis with polyneuropathy. The Vyndaqel/Vyndamax pivotal trial, which took place prior to when Onpattro and Tegsedi were under investigation for amyloidosis, did not include patients who were taking investigational drugs. The pivotal trials for Amvuttra, Onpattro, Tegsedi, and Wainua did not allow concurrent use of tetramer stabilizers (e.g., tafamidis, diflunisal). The pivotal trials for Amvuttra and Wainua did not allow concurrent use of Onpattro or Tegsedi (Amvuttra was not approved when Eplontersen was under investigation). A Phase II open-label extension study (n = 27) included 13 patients who were treated concomitantly with Onpattro and tafamidis.⁵ Following 24 months of treatment, there was no significant difference in the median serum transthyretin percent change from baseline with concomitant Onpattro and tafamidis (-80%) vs. Onpattro monotherapy (-88%). A scientific statement from the AHA notes that there is little data to support combination therapy for these products.³
- 2. Coverage is not recommended for circumstances not listed in the Recommended Authorization Criteria. Criteria will be updated as new published data are available.**

REFERENCES

1. Wainua™ subcutaneous injection [prescribing information]. Wilmington, DE: AstraZeneca; December 2023.
2. Alcantara M, Mezi MM, Baker SK, et al. Canadian guidelines for hereditary transthyretin amyloidosis polyneuropathy management. *Can J Neuro Sci.* 2022;49:7-18.
3. Kittleson MM, Maurer MS, Ambardekar AV, et al; on behalf of the American Heart Association Heart Failure and Transplantation Committee of the Council on Clinical Cardiology. AHA scientific statement: cardiac amyloidosis: evolving diagnosis and management. *Circulation.* 2020;142:e7-e22.
4. McDonagh TA, Metra M, Adamo M, et al. 2021 ESC guidelines for the diagnosis and treatment of acute and chronic heart failure. *Eur Heart J.* 2021;42:3599-3726.
5. Lin H, Merkel M, Hale C, Marantz JL. Experience of patisiran with transthyretin stabilizers in patients with hereditary transthyretin-mediated amyloidosis. *Neurodegener Dis Manag.* 2020;10(5):289-300.
6. Coelho T, Ando Y, Benson MD, et al. Design and rationale of the global Phase 3 NEURO-TTtransform Study of antisense oligonucleotide AKCEA-TTR-L_{rx} (ION-682884-CS3) in hereditary transthyretin-mediated amyloid polyneuropathy. *Neurol Ther.* 2021;10:375-389.

HISTORY

Type of Revision	Summary of Changes	Review Date
New Policy	--	01/03/2024